Celsion Corp (NASDAQ:CLSN) shares jumped 17% in pre-market trade after it unveiled another round of survival data that underscored the potential of its technology in patients with primary liver cancer.
ThermoDox is a heat-activated method of carrying chemotherapy to a target area.
It was used in combination with radio frequency ablation, where heat generated from radio waves is used to a kill a tumour.
However with some tumours the outer edges, or margins, survive the process. ThermoDox uses heat sensitive liposomes that contain doxorubicin to kill off the remnant cancer.
The latest update from the clinical trial revealed that 41% of the patient group saw a significant improvement in survival when using the combination therapy compared with those people simply receiving radio frequency ablation (RFA) alone.
The data were even more compelling in the Chinese patient population.
“Data from the HEAT Study have consistently been a foundation and provides additional evidence for our thesis that ThermoDox, when combined with RFA standardised to a minimum of 45 minutes for intermediate size lesions has the potential to significantly improve survival in primary liver cancer, where the current overall survival rate is far too short,” said Nicholas Borys, Celsion's chief medical officer.
“These findings, if borne out in our ongoing OPTIMA trial, will position ThermoDox as a potentially curative treatment in primary liver cancer.”